Hepatoprotective effect of BPC 157, A 15-aminoacid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin
1993; Elsevier BV; Volume: 53; Issue: 18 Linguagem: Inglês
10.1016/0024-3205(93)90589-u
ISSN1879-0631
AutoresPredrag Sikirić, Sven Seiwerth, Željko Grabarević, Rudolf Ručman, Marijan Petek, Ivo Rotkvić, Branko Turković, Vjekoslav Jagić, Boris Mildner, Marko Duvnjak, Z Danilović, M. Kolega, Ahmet Sallmani, Sanja Đačić, Milan Dodig, Nada Lang, Jadranka Šeparović, Vedran Ćorić, Velimir Šimičević, Krešimir Bulić, Marija Veljača, Nevena Skroza, Marko Banić, Tomislav Brkić, Gojko Buljat, Stjepan Miše, Dražen Lučinger, Miljenko Bura,
Tópico(s)Liver Disease Diagnosis and Treatment
ResumoThe hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct + hepatic artery ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + hepatic artery ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective eefect of BPC 157, possible clinical application in liver diseases is now warranted.
Referência(s)